AuntMinnie

MARCH 7, 2024

In terms of 2023 spending, the average radiopharmaceutical expenditure per fixed PET site is estimated to be $517,000. In 2023, 38% of PET systems were operated by the PET department, 28% by nuclear medicine, 24% by radiology/imaging, 5% by radiation oncology, and 2% by molecular imaging.

PET Scan 115

PET Scan Nuclear Medicine Radiation Oncology Radiopharmaceuticals 115

AuntMinnie

JUNE 20, 2024

F-18 fluorocholine (FCH) PET/CT could be a first-line technique over technetium-99m sestamibi (Tc-99m MIBI) SPECT/CT for imaging parathyroid tumors prior to surgery, according to a study published June 20 in JAMA Otolaryngology-Head & Neck Surgery. No complications occurred. The full study is available here.

Radiopharmaceuticals 105

Radiopharmaceuticals Radiation Imaging Clinic 105

TTG Imaging Solutions

MAY 5, 2023

Enhances TTG’s continued commitment to offer a full spectrum of high-quality and cost-effective service solutions in the cardiology and radiation oncology markets PITTSBURGH, PA (May 5, 2023) – TTG Imaging Solutions, LLC (TTG) announced today the acquisition of Digirad Health, Inc., headquartered in Suwanee, GA. Digirad Health, Inc.

Imaging 52

Imaging Radiopharmaceuticals Radiation Oncology Nuclear Medicine 52

Future Teleradiology

NOVEMBER 27, 2023

This blog post sheds light on recent breakthroughs in nuclear medicine, illuminating the innovative advancements that are shaping the future of medical imaging and treatment. Discuss how these advancements enhance imaging capabilities, providing clearer insights into physiological processes.

Nuclear Medicine 52

Nuclear Medicine Radiopharmaceuticals Imaging Modalities Radiation 52

Imaging Technology

AUGUST 29, 2023

Once securely attached to a targeting molecule, the chelated Cu-67 delivers therapeutic doses of radiation to destroy cancer cells with limited damage to healthy tissue. It supports a sustainable future for radiopharmaceuticals unencumbered by manufacturing, logistical and environmental issues inherent to many radiopharmaceuticals.

Pharmaceutical 75

Pharmaceutical Radiopharmaceuticals Clinic Medical 75

Imaging Technology

JULY 5, 2023

Ac-225 is a high energy alpha-emitting radioisotope of increasing interest for clinical studies investigating the use of targeted radiopharmaceutical therapy, which combines select molecules with therapeutic radioisotopes to directly target and deliver therapeutic doses of radiation to destroy cancer cells in patients with serious disease.

Medical 63

Medical Radiopharmaceuticals Pharmaceutical Radiation 63

Imaging Technology

SEPTEMBER 27, 2023

PET imaging with POSLUMA reveals clinical information crucial to decision-making for men with prostate cancer, and we are excited to share further information with the radiation oncology community at ASTRO 2023,” said David E. Jani, MD, FASTRO, Department of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, Ga.,

Diagnostic 93

Diagnostic Radiation Oncology Radiation Clinic 93